Johan Bengzon

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 6

Top Topics

Transcription Factor

Magnetic Resonance

Papillary Thyroid

Top Venues

Molecular cancer therapeutics

Brain and behavior

NMR in biomedicine

This page only lists publications with an associated author ORCID identifier.

Publications

Francesco Trovato, Francesca Romana Stefani, Jiaxin Li, Oskar G Zetterdahl, Isaac Canals, Henrik Ahlenius, Johan Bengzon
Transcription Factor-Forced Astrocytic Differentiation Impairs Human Glioblastoma Growth In Vitro and In Vivo. Molecular cancer therapeutics 22 (2) (2023)
Gustav Cedergren Weber, Jonathan Timpka, Anna Rydelius, Johan Bengzon, Per Odin
Tumoral parkinsonism-Parkinsonism secondary to brain tumors, paraneoplastic syndromes, intracranial malformations, or oncological intervention, and the effect of dopaminergic treatment. Brain and behavior (2023)
Francesco Trovato, Francesca Romana Stefani, Jiaxin Li, Oskar G Zetterdahl, Isaac Canals, Henrik Ahlenius, Johan Bengzon
Transcription Factor-Forced Astrocytic Differentiation Impairs Human Glioblastoma Growth In Vitro and In Vivo. Molecular cancer therapeutics 22 (2) (2023)
Francesco Trovato, Francesca Romana Stefani, Jiaxin Li, Oskar G Zetterdahl, Isaac Canals, Henrik Ahlenius, Johan Bengzon
Transcription Factor-Forced Astrocytic Differentiation Impairs Human Glioblastoma Growth In Vitro and In Vivo. Molecular cancer therapeutics 22 (2) (2023)
Anina Seidemo, Ronnie Wirestam, Gunther Helms, Karin Markenroth Bloch, Xiang Xu, Johan Bengzon, Pia C Maly-Sundgren, Peter C M van Zijl, Linda Knutsson
Tissue response curve-shape analysis of dynamic glucose-enhanced and dynamic contrast-enhanced magnetic resonance imaging in patients with brain tumor. NMR in biomedicine (2022)
Francesco Trovato, Francesca Romana Stefani, Jiaxin Li, Oskar G Zetterdahl, Isaac Canals, Henrik Ahlenius, Johan Bengzon
Transcription Factor Forced Astrocytic Differentiation Impairs Human Glioblastoma Growth In Vitro and In Vivo. Molecular cancer therapeutics (2022)